D. Faltaos

发表

Phase I study of receptor tyrosine kinase (RTK) inhibitor, MGCD265, in patients (pts) with advanced solid tumors.

J. Christensen, G. Shapiro, H. Hurwitz, 2015 .

Phase I Study of Glesatinib (MGCD265) in Combination with Erlotinib or Docetaxel in Patients with Advanced Solid Tumors

D. Potvin, K. Papadopoulos, D. Rasco, 2022, Targeted Oncology.

Mocetinostat for patients with previously treated, locally advanced/metastatic urothelial carcinoma and inactivating alterations of acetyltransferase genes

G. Sonpavde, D. Potvin, M. Milowsky, 2018, Cancer.

Population pharmacokinetic study of methotrexate in patients with lymphoid malignancy

S. Urien, J. Hulot, V. Leblond, 2006, Cancer Chemotherapy and Pharmacology.

Use of an indirect effect model to describe the LDL cholesterol‐lowering effect by statins in hypercholesterolaemic patients

S. Urien, J. Hulot, P. Giral, 2006, Fundamental & clinical pharmacology.

Abstract P1-17-12: Preliminary data from a phase I/II, multicenter, dose escalation study of OP-1250, an oral CERAN/SERD, in subjects with advanced and/or metastatic estrogen receptor (ER)-positive, HER2-negative breast cancer

C. Harmon, P. Klein, P. Kushner, 2022, Cancer Research.

Phase I Study Evaluating Glesatinib (MGCD265), An Inhibitor of MET and AXL, in Patients with Non-small Cell Lung Cancer and Other Advanced Solid Tumors

D. Potvin, J. Christensen, Keunchil Park, 2022, Targeted Oncology.

Amethyst NSCLC trial: Phase 2, parallel-arm study of receptor tyrosine kinase (RTK) inhibitor, MGCD265, in patients (pts) with advanced or metastatic non-small cell lung cancer (NSCLC) with activating genetic alterations in mesenchymal-epithelial transition factor (MET).

P. Jänne, J. Nemunaitis, J. Christensen, 2016 .

A phase I/II multiple expansion cohort trial of MRTX849 in patients with advanced solid tumors with KRAS G12C mutation.

S. Ou, D. Potvin, J. Christensen, 2019, Journal of Clinical Oncology.

Evaluation of the spectrum selective RTK inhibitor sitravatinib in clear cell renal cell carcinoma (ccRCC) refractory to anti-angiogenic therapy (AAT).

C. Kyriakopoulos, D. Potvin, J. Christensen, 2018 .

P2.06-017 Amethyst NSCLC Trial: Phase 2 Study of MGCD265 in Patients with Advanced or Metastatic NSCLC with Activating Genetic Alterations in MET: Topic: Phase II + NK

P. Jänne, D. Potvin, L. Cavanna, 2017 .